Eswatini

Reimbursed Care Access

Eswatini maintains restrictive drug control laws (rooted in the Opium and Habit‑forming Drugs Act, 1922 and the Pharmacy Act, 1929) that broadly prohibit non‑medical possession, manufacture and distribution of classical psychedelics. Ketamine is an established anaesthetic in clinical use in Eswatini hospitals (and therefore available for medical indications), while modern, marketed psychedelic medicines such as esketamine (Spravato) and regulated MAP‑products (psilocybin, MDMA) show no evidence of national marketing authorization or reimbursement—access is effectively limited to accredited clinical care settings, importation under licence, or formal research. Reimbursement through public insurance or national programmes for psychedelic therapies is not established; private treatment or out‑of‑pocket payment and hospital provisioning (for ketamine anaesthesia) are the dominant pathways.